echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Clin Trans Gastroenterology: Indomethacin does not relieve the systemic inflammatory response syndrome of acute pancreatitis

    Clin Trans Gastroenterology: Indomethacin does not relieve the systemic inflammatory response syndrome of acute pancreatitis

    • Last Update: 2021-11-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Acute pancreatitis (AP) is one of the main reasons for hospitalization of patients in gastrointestinal emergency departments.
    The global incidence of AP is about 34/100,000
    .


    Although most patients with AP have mild clinical symptoms, 10%–15% of patients will develop severe AP (SAP) with persistent organ failure (OF), and about 2% of patients will die


    Acute pancreatitis (AP) is one of the main reasons for hospitalization of patients in gastrointestinal emergency departments.


     

    Non-steroidal anti-inflammatory drugs (NSAIDs) are effective inhibitors of COX enzymes, which can prevent the biosynthesis of prostaglandins and reduce the inflammatory response of AP
    .


    In view of the effectiveness, safety, availability, and affordability of non-selective NSAIDs, they are often used to prevent pancreatitis after endoscopic retrograde cholangiopancreatography


     

     

    This study is a single-center, double-blind, randomized, placebo-controlled trial
    .


    The included patients were those who had AP and SIRS within 72 hours after presentation, and those who did not have organ failure


     

    The results of the study showed that a total of 42 subjects (mean age 52 years, 55% male) were randomly assigned to the indomethacin group (n = 18) or placebo group (n = 24)
    .


    There were no significant differences between the indomethacin group and the placebo group in terms of changes in SIRS scores, the proportion of SIRS subjects, and the distribution of SIRS scores at 24, 48, and 72 hours after randomization


     

    This study confirms that rectal indomethacin can be safely administered within 48 hours; however, it is not superior to placebo in reducing SIRS or clinical progression in people at high risk of AP
    .


    Therefore, the treatment of rectal indomethacin is not recommended for all patients who are not contraindicated with non-steroidal anti-inflammatory drugs and are at risk of postoperative pancreatitis


    This study confirms that rectal indomethacin can be safely administered within 48 hours; however, it is not superior to placebo in reducing SIRS or clinical progression in people at high risk of AP


    Original source:

    Machicado, Jorge D.


    Rectal Indomethacin Does Not Mitigate the Systemic Inflammatory Response Syndrome in Acute Pancreatitis: A Randomized Trial.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.